Date 29 January 2021
Final
Situational
Assessment
Since the last situational assessment shared with the EMA and European Commission on 6 November 2020,
EFPIA/Vaccines Europe have regularly monitored the supply situation among their members. EFPIA and
Vaccines Europe members do not report any current shortages of medicines across the European Union.
While they currently have no shortages to report, our member companies pointed out the following risks of
shortages:
For Valium (diazepam), as a result of an increase of demand following stockouts of other suppliers. The
company is exploring options to increase supply and cover the demand.
For Depo-Provera Vials, due to the prioritization of Covid Vaccine production, one manufacturer site
will momentarily cease production as of 01-Feb-2021. The impact is a projected shortage of 1ml and
3ml & 3.3ml vials presentations, spread across all regions. The Depo-Provera syringe presentations are
not impacted by this event. Notification to affected EU Member States is on-going (the product is
nationally registered).
Without facing shortages for the time being, companies also reported the following challenges:
Increase of demand on some products,
Transportation capacity remains limited, with the Global air cargo capacity down by 18% and a shortage
of sea freight equipment limiting global sea freight capacity,
There are supply tensions on the provision of raw materials of biological products, since these raw
materials are also used in vaccines production.
1
EFPIA Brussels Office
Leopold Plaza Building Rue du Trône 108
B-1050 Brussels Belgium
Tel: + 32 (0)2 626 25 55
www.efpia.eu xxxx@xxxxx.xx